Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06137742 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
A Phase 1 study of Pulmonary Arterial Hypertension, sponsored by Pfizer.
- Active
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 20
- Study locations
NCT06137742: Active Phase 1 study of Pulmonary Arterial Hypertension, sponsored by Pfizer.
NCT06137742 is a Phase 1 study of Pulmonary Arterial Hypertension that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 96 participants, below the 461-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06137742, a Phase 1 study of Pulmonary Arterial Hypertension, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH). Part A: An investigator- and participant-blind, sponsor-open, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics (PK) of PF-07868489 in healthy adult participants. Part B: A 24-week, randomized, double blind, placebo-controlled study to assess the safety, tolerability, PK, and pharmacodynamics (PD) of PF-07868489 in adult participants with PAH.
Primary Outcome
Part A
Conditions Studied
Interventions
- DRUG PF-07868489
- DRUG Placebo for PF-07868489
Study Locations (20)
California
- Anaheim Clinical Trials, LLC - Anaheim
- UCI Health - Costa Mesa - Costa Mesa
- UCI Health Center for Innovative Health Therapies (CIHT) - Orange
- University of California, Irvine Medical Center - Orange
- UC Davis Health Medical Center - Sacramento
- University of California Davis Health - Sacramento
- UCSF Health St. Mary's Hospital - San Francisco
- UCSF Helen Diller Medical Center at Parnassus Heights - San Francisco
North Carolina
- Eastowne 100 Medical Office Building - Chapel Hill
- Eastowne Medical Office Building - Clinical Research Unit - Chapel Hill
- UNC Health - Eastowne Medical Office - Chapel Hill
- UNC Hospitals - Chapel Hill
- Investigational Drug Services Pharmacy - Morrisville
Kentucky
- Norton Hospital - Louisville
- Norton Pulmonary Specialists - Louisville
New York
- Icahn school of medicine at Mount Sinai - New York
- Mount Sinai Hospital - New York
Rhode Island
- Rhode Island Hospital - Providence
- Center for Advanced Lung Care - Providence
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2023-11-17 |
| Est. Completion | 2026-09-02 |
| Phase | Phase 1 |
What the registry record for NCT06137742 still lists
NCT06137742 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 461-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which PF-07868489 is the first listed.
NCT06137742 names 20 study sites across 6 states, led by California, North Carolina, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06137742 about?
NCT06137742 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension". The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH). Part A: An investigator- and participant-blind, sponsor-open, placebo-controlled, single ascending dose study to asses...
What is the current status of trial NCT06137742?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2023-11-17. Estimated completion is 2026-09-02.
What conditions does trial NCT06137742 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT06137742?
The interventions under investigation include: PF-07868489 (DRUG), Placebo for PF-07868489 (DRUG).
Who is sponsoring clinical trial NCT06137742?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06137742 being conducted?
This trial has 20 study locations across California, Colorado, Kentucky, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06137742's enrollment target sits among peer trials
96 20th of 63 higher than 44 of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
Subcutaneous Elafin in Healthy Subjects
COMPLETED · Phase 1
-
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
COMPLETED · Phase 1
-
A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension
COMPLETED · Phase 1
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI